Lindus Health and Quotient Sciences have entered a strategic collaboration to support biotech and pharmaceutical sponsors with subject recruitment for Phase I-IIa clinical trials.
This collaboration aims to provide a smoother transition from first-in-human (FIH) to proof-of-concept (POC) studies.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to Lindus, the drug’s development process has traditionally involved working with several vendors across pre-clinical and clinical stages, often leading to knowledge gaps and operational setbacks.
The new partnership seeks to address these challenges by integrating Quotient Sciences’ early clinical and drug development offerings with Lindus Health’s capabilities in recruiting patients and delivering later-stage trials.
Quotient Sciences is said to conduct more than 70 Phase I trials annually at its facilities in the US and UK, focusing on FIH to POC programmes and a variety of clinical pharmacology trials.
Its Translational Pharmaceutics model is designed to connect drug product development with early clinical offerings, aiming to speed up the progression from formulation to FIH trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLindus Health also brings experience in Phase II trials and comprehensive trial delivery across the UK, the US, and Europe, covering a range of therapeutic areas such as neuropsychiatry, respiratory, dermatology and cardiometabolic.
By joining forces, the two entities aim to offer a unified clinical development process, removing the need for sponsors to separately identify and assess Phase I and later-stage contract research organisations (CROs).
The partnership is intended to address obstacles in patient recruitment and streamline the transition between development phases and CRO partners to expedite the delivery of new treatments.
Lindus Health co-CEO Michael Young said: “This partnership underscores our commitment to removing bottlenecks in the clinical development lifecycle.
“By collaborating with Quotient Sciences, we are creating a comprehensive development pathway that allows biotech companies to move through a contiguous experience from FIH studies through to pivotal trials.
“Sponsors get the specialised Phase I expertise they need at the beginning, with recruitment support from the same proven end-to-end CRO partner ready to scale their programmes as they progress.”
In April 2025, the UK’s research and development (R&D) funding agency ARIA granted funds to Lindus for the development of safe AI for clinical trial design.
